Cargando…
A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
BACKGROUND AND PURPOSE: Two clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia G...
Autores principales: | Di, Li, Shen, Faxiu, Wen, Xinmei, Lu, Yan, Zhu, Wenjia, Wang, Min, Da, Yuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971191/ https://www.ncbi.nlm.nih.gov/pubmed/35371086 http://dx.doi.org/10.3389/fimmu.2022.839075 |
Ejemplares similares
-
A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis
por: Heckmann, Jeannine M, et al.
Publicado: (2011) -
Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020) -
VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis
por: Su, Shengyao, et al.
Publicado: (2021) -
Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023) -
Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)